Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Cell Biochem Funct ; 40(7): 773-783, 2022 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-36111697

RESUMO

Obesity is associated with other diseases such as diabetes and cancer. Botryosphaeran, a fungal (1→3)(1→6)-ß-d-glucan, is described to present antimutagenic, hypoglycemic, hypocholesterolemic, and antitumor activities when administered by gavage over 15 days in rats and mice. Thus, the present study aims to analyze the metabolic effects of Botryosphaeran (12 mg/kg body weight/day) treatment over 30 days in obese Wistar male rats. Obesity was induced in the rats by a high-fat/high-sugar diet for 8 weeks. Control rats received a standard diet. On the 5th week, Botryosphaeran treatment commenced. Groups: control, obese, and obese+Botryosphaeran 30 days. In the 8th week, obesity was characterized. Feed intake, glucose and lipid profiles, glucose tolerance, and insulin sensitivity were analyzed. Obese rats showed accumulation of visceral adipose tissue, reduction of muscle mass, glucose intolerance, insulin resistance, hyperglycemia, and dyslipidemia. Botryosphaeran effectively reduced weight gains and the accumulation of retroperitoneal adipose tissue, corrected the levels of glucose, triglycerides, and very low-density lipoprotein-cholestrol, and improved insulin sensitivity. Treatment for 30 days was effective in maintaining the beneficial effects demonstrated by this ß-glucan when administered for 15 days without promoting side effects. Treatment with (1→3)(1→6)-ß- d-glucan presented anti-obesogenic and beneficial metabolic effects in Wistar rats; important for the treatment of obesity and its comorbidities.


Assuntos
Resistência à Insulina , beta-Glucanas , Animais , Glicemia , Dieta Hiperlipídica , Glucanos/farmacologia , Glucose , Hipoglicemiantes/farmacologia , Hipoglicemiantes/uso terapêutico , Insulina , Lipoproteínas LDL , Masculino , Camundongos , Obesidade/metabolismo , Ratos , Ratos Wistar , Açúcares , Triglicerídeos/metabolismo , beta-Glucanas/farmacologia
2.
Arch. endocrinol. metab. (Online) ; 60(6): 582-586, Nov.-Dec. 2016. tab, graf
Artigo em Inglês | LILACS | ID: biblio-827786

RESUMO

ABSTRACT Objective The current study was aimed at analyzing sarcoplasmic reticulum Ca2+ ATPase (Serca2) and ryanodine receptor type 2 (Ryr2) gene expression in rats subjected to surgery that induced HF and were subsequently treated with T4 using physiological doses. Materials and methods HF was induced in 18 male Wistar rats by clipping the ascending thoracic aorta to generate aortic stenosis (HFS group), while the control group (9-sham) underwent thoracotomy. After 21 weeks, the HFS group was subdivided into two subgroups. One group (9 Wistar rats) with HF received 1.0 µg of T4/100 g of body weight for five consecutive days (HFS/T4); the other group (9 Wistar rats) received isotonic saline solution (HFS/S). The animals were sacrificed after this treatment and examined for signs of HF. Samples from the left ventricles of these animals were analyzed by RT-qPCR for the expression of Serca2 and Ryr2 genes. Results Rats with HF developed euthyroid sick syndrome (ESS) and treatment with T4 restored the T3 values to the Sham level and increased Serca2 and Ryr2 gene expression, thereby demonstrating a possible benefit of T4 treatment for heart function in ESS associated with HF. Conclusion The T4 treatment can potentially normalize the levels of T3 as well elevated Serca2 and Ryr2 gene expression in the myocardium in heart failure rats with euthyroid sick syndrome.


Assuntos
Animais , Masculino , Tiroxina/administração & dosagem , Síndromes do Eutireóideo Doente/tratamento farmacológico , Canal de Liberação de Cálcio do Receptor de Rianodina/efeitos dos fármacos , Estenose da Valva Aórtica/complicações , Tiroxina/uso terapêutico , Tri-Iodotironina/efeitos dos fármacos , Síndromes do Eutireóideo Doente/complicações , Síndromes do Eutireóideo Doente/genética , RNA Mensageiro/metabolismo , Expressão Gênica/efeitos dos fármacos , Ratos Wistar , Canal de Liberação de Cálcio do Receptor de Rianodina/genética , Modelos Animais , ATPases Transportadoras de Cálcio do Retículo Sarcoplasmático/efeitos dos fármacos , ATPases Transportadoras de Cálcio do Retículo Sarcoplasmático/genética , Insuficiência Cardíaca/complicações
3.
Arch Endocrinol Metab ; 60(6): 582-586, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27737323

RESUMO

OBJECTIVE: The current study was aimed at analyzing sarcoplasmic reticulum Ca2+ ATPase (Serca2) and ryanodine receptor type 2 (Ryr2) gene expression in rats subjected to surgery that induced HF and were subsequently treated with T4 using physiological doses. MATERIALS AND METHODS: HF was induced in 18 male Wistar rats by clipping the ascending thoracic aorta to generate aortic stenosis (HFS group), while the control group (9-sham) underwent thoracotomy. After 21 weeks, the HFS group was subdivided into two subgroups. One group (9 Wistar rats) with HF received 1.0 µg of T4/100 g of body weight for five consecutive days (HFS/T4); the other group (9 Wistar rats) received isotonic saline solution (HFS/S). The animals were sacrificed after this treatment and examined for signs of HF. Samples from the left ventricles of these animals were analyzed by RT-qPCR for the expression of Serca2 and Ryr2 genes. RESULTS: Rats with HF developed euthyroid sick syndrome (ESS) and treatment with T4 restored the T3 values to the Sham level and increased Serca2 and Ryr2 gene expression, thereby demonstrating a possible benefit of T4 treatment for heart function in ESS associated with HF. CONCLUSION: The T4 treatment can potentially normalize the levels of T3 as well elevated Serca2 and Ryr2 gene expression in the myocardium in heart failure rats with euthyroid sick syndrome.


Assuntos
Síndromes do Eutireóideo Doente/tratamento farmacológico , Canal de Liberação de Cálcio do Receptor de Rianodina/efeitos dos fármacos , ATPases Transportadoras de Cálcio do Retículo Sarcoplasmático/efeitos dos fármacos , Tiroxina/administração & dosagem , Animais , Estenose da Valva Aórtica/complicações , Síndromes do Eutireóideo Doente/complicações , Síndromes do Eutireóideo Doente/genética , Expressão Gênica/efeitos dos fármacos , Insuficiência Cardíaca/complicações , Masculino , Modelos Animais , RNA Mensageiro/metabolismo , Ratos Wistar , Canal de Liberação de Cálcio do Receptor de Rianodina/genética , ATPases Transportadoras de Cálcio do Retículo Sarcoplasmático/genética , Tiroxina/uso terapêutico , Tri-Iodotironina/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...